Transient bradycardia during <sup>177</sup>Lu-DOTATATE therapy: A clinically manageable phenomenon with increased risk in patients with cardiac enlargement. [PDF]
Ann Nucl MedYamada H +9 more
europepmc +1 more source
Radiomics Analysis for Clinical Decision Support in 177Lu-DOTATATE Therapy of Metastatic Neuroendocrine Tumors using CT Images. [PDF]
J Biomed Phys EngBehmanesh B +4 more
europepmc +1 more source
Very good effect of rescue treatment with <sup>177</sup>Lu-DOTATATE in the patient with advanced metastatic atypical lung carcinoid. [PDF]
Rep Pract Oncol RadiotherPoniatowska ME +6 more
europepmc +1 more source
Molecular Deconvolution of Circulating "Other Cells": A Reliable Predictive Marker of Therapy Response and Survival in Neuroendocrine Tumor Patients Receiving <sup>177</sup>Lu-DOTATATE PRRT. [PDF]
Cancer MedPadwal MK, Parghane RV, Basu S, Basu B.
europepmc +1 more source
Evaluation of Reduced Single-Photon Emission Computed Tomography Imaging Protocols and Software Variability in <sup>177</sup>Lu-DOTATATE Dosimetry: Protocol for an Exploratory Observational Trial. [PDF]
JMIR Res ProtocYagihashi T +7 more
europepmc +1 more source
Success of <sup>177</sup>Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor. [PDF]
Endocr OncolWolf KI +5 more
europepmc +1 more source
CHARACTERIZATION OF BINDING MECHANISM, INTERNALIZATION AND EXCRETION OF 177LU-DOTATATE
EANM InnovationHadis Westin +2 more
openaire +1 more source
Delayed and Long-Lasting Response to 177Lu-DOTATATE in a Head and Neck Paraganglioma: Case Report and Literature Review. [PDF]
Case Rep OncolRuffini Egea S +7 more
europepmc +1 more source